Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 34Lymphoid 12Thoracic 11Other hematologic neoplasm 6Gastrointestinal 5Plasma cell 3Genitourinary 3Sarcoma 2Dermatologic 2Other 1

Conditions

Obesity 112Neoplasms 43Sexual Dysfunction, Physiological 31Polycystic Ovary Syndrome 27Overweight 18Breast Neoplasms 18Diabetes Mellitus 16Colorectal Neoplasms 16Dyspnea 14Diabetes Mellitus, Type 2 13Obesity, Morbid 12Mucositis 12Constipation 12Depression 11Prostatic Neoplasms 10Lung Neoplasms 10Hypertension 10Pulmonary Disease, Chronic Obstructive 9Non-alcoholic Fatty Liver Disease 9Metabolic Syndrome 9Insulin Resistance 9Motor Activity 8Cardiovascular Diseases 8Renal Insufficiency, Chronic 7Opioid-Induced Constipation 7Heart Failure 7Asthma 7Sarcopenia 6Rectal Neoplasms 6Multiple Myeloma 6

Interventions

Hematologic Tests 1Echocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Cardiotoxicity × Other × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡